Heska Corporation, a global provider of advanced veterinary diagnostic and specialty products and solutions, has completed the previously announced acquisition of LightDeck Diagnostics, a pioneer in planar waveguide fluorescence immunoassay diagnostics.
Acquiring LightDeck - which previously traded as MBio Diagnostics and boasts strong manufacturing capabilities and research and development expertise - represents a key advancement in Heska’s strategic plan to accelerate research and development and manufacturing capabilities at scale.
Founded in 2009 in Boulder, Colorado, LightDeck has developed a scalable and innovative platform based on an extensive intellectual property for rapid and accurate point of care diagnostics. LightDeck's planar waveguide technology optimises laser-activated fluorescence and microfluidics to produce point of care cartridge-based testing for quantitative results in minutes with inexpensive, easy-to-use workflow.
LightDeck's facilities include fully equipped laboratories for assay development, controlled manufacturing capabilities, and a new, state-of-the-art, fully automated facility in Longmont, Colorado that will further advance in-clinic testing manufacturing at scale. The Longmont facility, anticipated to go online in 2023, will dramatically increase Heska's manufacturing production capacity and research and development efforts in furtherance of several potential blockbuster testing platforms, including the company's exclusive canine cancer screening platform anticipated to launch in 2023.
Heska Corporation manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products in North America and internationally. Both segments include point-of-care laboratory testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. For more information, please visit www.heska.com.